Physiomics to provide cardiac toxicity modelling

RNS Number : 7155A

Physiomics PLC

25 March 2013

 

 25 March 2013

Physiomics plc 

(the "Company" or "Physiomics") 

Physiomics to provide cardiac toxicity modelling service 

Physiomics plc (AIM: PYC), the Oxford, UK-based systems biology company, is pleased to announce the launch of its new cardiac toxicity modelling service. This new model predicts the risk of a fatal heart arrhythmia known as Torsade de Pointes, using low cost and relatively easy to obtain lab-based data. From 1990 to 2010, a dozen compounds were withdrawn from the market because of association with Torsade de Pointes. 

 It is understood that the current industry standard tool to predict cardiac toxicity risk is only partially predictive. The Physiomics method aims to reduce the number of candidates incorrectly rejected and also to reduce the number of compounds incorrectly advanced into costly clinical trials. The directors believe it is significantly better than the available published models at predicting cardiac toxicity side effects.

 Further information on this cardiac toxicity platform can be found on the Physiomics plc website.

 Dr Mark Chadwick, CEO of Physiomics, commented:  "This new model fits well with our overall strategy of reducing the risk, timelines and costs associated with drug discovery and development.  Applicable across all therapeutic areas, it should provide access to a broader range of customers worldwide."

 Enquiries:

 Physiomics plc                                                  

Mark Chadwick 

[phone]

WH Ireland Limited

Katy Mitchell

[phone]

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million¹.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002

 

END

 

 

NRANKBDNOBKDKNB